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ABSTRACT   Brain-derived neurotrophic factor (BDNF) is necessary for nerve growth. BDNF 
is expressed in the dorsal root ganglion (DRG) and modulates pain transduction from peripheral 
nociceptors. TrkB, which is a BDNF receptor with a tyrosine kinase domain, acts as a pain 
modulator on the cell membrane of second neuron. If an exogenous truncated TrkB lacking 
a tyrosine kinase domain can competitively block the binding of BDNF to endogenous TrkB, 
inhibitory effects on pain are expected. We constructed two expression vectors coding truncated 
TrkB-GFP fusion proteins, lacking intracellular tyrosine kinase domain, with and without the 
transmembrane domain. By transfection of the vectors to HEK293 cells, the expression and 
localization of the modified receptor proteins were confirmed. The truncated TrkB with the 
transmembrane domain, TM (+), was localized on cell membrane surface of the transfected 
cells, and capable of BDNF binding on cell surface. TM (-) without the transmembrane domain 
was secreted from the transfected cells, and the secreted TrkB protein was confirmed the 
capability for binding with BDNF by pull-down assay. Furthermore, we developed a rat model 
of cancerous osteocopic pain for evaluating an analgesic effect of the modified TrkB vectors on 
cancer pain. Pain-related behavior, as assessed by von Frey tests, indicated hyperalgesia after 
cancer cell administration. BDNF expression was higher on the affected side of the DRG at 
the third lumbar vertebra L3 than on the unaffected side. When the modified TrkB vectors were 
administrated to the cancer pain model rats, both the TM (+) and TM (-) vector administration 
groups exhibited an analgesic effect. These results suggest that the modified TrkB receptors 
and their vectors are applicable as molecular targeted drugs for pain control in cancer patients.
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INTRODUCTION
   The incidence of cancer is rising because of 
the increasing elderly population in Japan, and 
approximately one-third of this population dies from 
cancer１）. Approximately 70-80% of patients report 
severe pain associated with terminal cancer. Bone 
metastases cause decreased quality of life, including 
pain and pathological fractures２）. The treatment of 
cancer-related bone pain is challenging３） and is an 
important component of medical care４）. Analgesia 
is often insufficient and the opioid quantity required 
for treatment may be limited by side effects５）. It 
is necessary to establish new sedative methods; 
accordingly, we developed a new approach to 
alleviate cancer pain.
   Brain-derived neurotrophic factor (BDNF) is 
associated with pain. BDNF expression is increased 
in various pain models, including acute pain and 
neuropathic pain models６－８）, and in the dorsal root 
ganglion (DRG) of the third lumbar vertebra L3 in a 
tibia cancer pain model９）.
   BDNF is a member of the neurotrophins family, 
proteins necessary for nervous system development, 
growth, and maintenance10）, which function by 
binding to specific receptors11）. BDNF binds to 
TrkB receptors and may be involved in the sensory 
nervous system as a pain modulator12）.
   The mechanism by which BDNF transmits pain 
information is unknown; however, it is thought to 
involve Na ion channels13）. When BDNF binds to 
TrkB, the Nav1.9 channel opens, which induces the 
depolarization of cells and signal transmission13）. 
In a neuropathic pain model, BDNF expression 
increases. When BDNF acts on TrkB of the spinal 
cord, it inhibits K+-Cl- cotransporter 2, egests 
Cl- extracellularly, and the intracellular potential 
shifts to the anion side. This results in allodynia 
via the depolarization of cells after the release of 
γ-aminobutyric acid by tactile stimulation from 
an inhibitory connector neuron14）. In BDNF’s 
association with pain, its binding to a specific TrkB 
receptor is important.
   BDNF is generated within a cell body of the 
DRG in response to pain in the first sensory neuron 
and is transported in an orthodromic direction 
to the second neuron. Upon BDNF binding to 
TrkB on the second neuronal cell membrane, 
autophosphorylation occurs in the intracellular 
tyrosine kinase domain of TrkB, which opens the 
Na ion channel directly or indirectly. An inflow of 
Na+ occurs, the membrane potential changes, and 
pain information is transmitted15）.
   We postulated that an analgesic effect might 
be achieved by the competitive inhibition of the 
interaction between BDNF and TrkB. Therefore, we 
constructed vectors encoding truncated TrkB lacking 
the intracellular tyrosine kinase domain, confirmed 
their expression and the binding of BDNF to the 
truncated TrkB, and examined their analgesic effects 
on a cancer pain.
MATERIALS AND METHODS
Cell culture
   The  ra t  breas t  cancer  ce l l  l ine  MRMT-1 
was provided by the Cell Resource Center for 
Biomedical Research, Tohoku University (Miyagi, 
Japan). The human normal embryonic kidney cell 
line HEK293 was purchased from the American 
Type Culture Collection (ATCC, Manassas, VA, 
USA). MRMT-1 and HEK293 cells were cultured 
in RPMI 1640 and DMEM medium, respectively, 
supplemented with 10% fetal bovine serum, 200 U/
mL penicillin, 200 μg/mL streptomycin, and 300 
mg/mL L-glutamine, and incubated at 37 ℃ in a 
humidified atmosphere of 5% CO2.
Plasmids
   Based on the rat TrkB gene (GenBank Accession, 
M55291), two truncated TrkB cDNAs were obtained 
using polymerase chain reaction (PCR) as described 
below. Using the sense primer TrkB-FW1 (5′-GGA 
TCC GCC ATG TCG CCC TGG CCG AGG TG-3′, 
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including the restriction endonuclease BamHI site) 
targeting the protein synthesis initiation region 
and the antisense primer TrkB-RV1 (5′-GAA TTC 
ATG CTC CCG ATT GGT TTG GTC-3′, including 
an EcoRI site) targeting the region upstream of 
transmembrane region, the extracellular region 
of TrkB without the transmembrane domain 
was amplified by PCR from the rat cDNA. The 
extracellular region of TrkB containing the 
transmembrane domain was amplified by PCR 
using the sense primer TrkB-FW1 and the antisense 
primer TrkB-RV2 (5′-GAA TTC TGG GCC TTT 
CAT GCC AAA CTT G-3′, including an EcoRI 
site) targeting the downstream region of the 
transmembrane domain. Each PCR product was 
cloned into the EcoRV site of pBluescript KS, and 
confirmed by DNA sequencing. Subsequently, 
each TrkB gene was digested using BamHI and 
EcoRI, and the resultant fragment inserted into the 
pCMVscript-EGFP vector digested with BamHI 
and EcoRI. The pCMVscript-EGFP vector codes 
a fused protein of enhanced green fluorescent 
protein (EGFP), FLAG-tag, and S-protein tag 
downstream of CMV promoter. Sequencing analysis 
was used to confirm the amino acid frame of the 
TrkB gene fused with the EGFP, FLAG-tag, and 
S-protein tag. A TM (-) vector that lacked the 
transmembrane domain, and a TM (+) vector with 
the transmembrane domain were created. The 
pCMVscript-EGFP was used as an empty vector in 
the following experiments.
Transfection and BDNF binding assay
   The empty vector, the TM (-) vector, and the TM 
(+) vector were introduced into HEK293 cells, using 
Lipofectamine 2000 (Invitrogen, Tokyo, Japan). 
Twenty-four hours after transfection, the expression 
levels of each modified receptor-EGFP fusion 
protein were observed using an Olympus IXL71 
(Olympus, Tokyo, Japan) fluorescence microscope. 
Localization of TM (+) protein on cell membrane 
was measured by confocal microscope system 
LSM780 (Carl Teiss, Jena, Germany) and imaging 
software ZEN2011 (Carl Teiss).
   After the TM (+) vector or empty vector was 
transfected into HEK293 cells on an 8-well culture 
slide (BD Falcon, Franklin Lakes, NJ, USA), the 
cells were cultured for 24 h, and BDNF was added 
(ab9794, mature type; Abcam, Cambridge, UK). 
After 1 h, the cells were washed and cultured in 
OPTI-MEM culture media (Invitrogen) with an 
anti-BDNF rabbit antibody (ab9793; Abcam), Cy3-
labeled anti-rabbit antibody, and 10% fetal bovine 
serum for 3 h. Fluorescence observations of the 
BDNF binding capability of TM (+) were conducted 
using an Olympus IXL71 fluorescence microscope.
Pull-down assay and western blotting analysis
   The TM (-) vector or the empty vector was 
introduced into HEK293 cells, and the supernatant 
was collected from the culture medium after 72 
h. Protease inhibitors (10 μL; Sigma, St. Louis, 
MO, USA) and 500 ng of BDNF protein (ab9794, 
mature type; Abcam) were added to 1 mL of the 
supernatant and mixed for 16 h at 4 ℃. After 
mixing with S-protein agarose beads (50 μL; 
Novagen, Madison, WI, USA) for 3 h at 4 ℃, the 
solution was centrifuged at 5,000 rpm for 3 min, 
the S-protein agarose complex was electrophoresed 
on an SDS-polyacrylamide gel, and blotted onto 
a polyvinylidene fluoride membrane. Anti-FLAG 
mouse antibody (Sigma; F3165) for detecting TM 
(-) protein, and anti-BDNF rabbit antibody (ab9793; 
Abcam) for detecting BDNF were added. Anti-
mouse antibody or anti-rabbit antibody (Vectastain 
ABC-AP Kit; Vector Laboratories, Burlingame, 
CA, USA), and CDP-star (New England BioLabs, 
Ipswich, MA, USA), a substrate of alkaline 
phosphatase, were reacted. Chemiluminescence was 
detected using the LAS-1000 (FUJIFILM, Tokyo, 
Japan).
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Animals
   All experiments in this study were performed 
according to the protocol  approved by the 
Institutional Animal Care and Use Committee of 
Kawasaki Medical School (approval number 14-
087).
   A cancerous osteocopic model was created 
according to previously described methods９，16）. 
Male Wistar rats, at 7 weeks of age and weighing 
190 - 210 g, were used in the study. The tibia of 
the left leg was exposed to light under general 
anesthesia with 3% sevoflurane, and the epiphyseal 
growth plate was punctured 5 mm on the tip side 
from the knee with a 23-G needle. Then, 3.0 × 
103/10 μL MRMT-1 rat breast cancer cells were 
injected at the site. The injection site was sealed 
with bone wax, and the wound was closed.
Radiological analysis
   Cancer cell growth was observed by simple 
X-rays; laterality was confirmed by photographing 
both proximal tibias using X-ray irradiation 
apparatus (ALOKA, Hitachi Healthcare, Tokyo, 
Japan). X-ray irradiation was conducted under 
general anesthesia with sevoflurane after von Frey 
tests at days 0, 7, and 14. All procedures, including 
MRMT-1 inoculation and vector administration, 
were performed after scanning.
Pain evaluation
   Pain was evaluated using the von Frey test with 
von Frey filaments (TACTILE TEST AESTHSIO, 
Muromachi Kikai Co., Tokyo, Japan). Filaments of 
0.4, 0.6, 1.0, 1.4, 2.0, 4.0, 6.0, 8.0, and 15.0 g were 
used. The 50% paw withdrawal threshold (PWT) 
of pain was calculated as an indicator of pain 
irritation17）. The von Frey tests were performed in a 
plastic cage (10 × 13 × 15 cm3), on which a wire 
mesh was installed to facilitate access to the plantar 
paw surface. After a rat rested quietly in the cage in 
a dark room for more than 30 min, measurements 
were obtained. Cancer cell inoculation day was 
considered as day 0 and measurements were 
obtained on days 0, 2, 5, 7, 9, 12, and 14. The 
researcher was blinded to the presence or absence of 
vector administration and the precise vector that was 
used.
Vector administration
   A dorsal skin incision from L3 to L6 was made 
under general anesthesia on day 7, and the lumbar 
level was identified from the vertebra spinous 
process and pelvis. A 23-G needle was inserted 
into the spinal cord subarachnoid space from the 
muscular fasciae of L5/6 and a sterilized catheter 
(polyethylene tube, inner diameter 0.2  mm, 
outer diameter 0.5 mm) was inserted from the 
intussuscipiens. The catheter tip was maintained 
in the vicinity of L3 (6 cm from the puncture site 
of the muscular fasciae) and the vector (1 μg/μL, 
10 μL) was administered with transfection reagent 
GenomONE (HVJ Envelope VECTOR KIT, 1 μg/
μL, 10 μL; ISHIHARA SANGYO KAISHA, 
LTD., Osaka, Japan) to the site. The three vector-
administered groups were the TM (-) group, the 
TM (+) group, and the empty vector group. An 
additional group, the vector non-administration 
group, was subjected to reagent transfection without 
a vector.
RNA extraction and quantitative real-time reverse 
transcription-PCR (qRT-PCR)
   After pain was evaluated, the rats were decapitated 
under general anesthesia with sevoflurane and 
the bilateral L3 DRG and the L3 spinal cord were 
resected. RNA was extracted from the tissue 
samples, using an RNeasy Lipid Tissue Mini Kit 
(Qiagen, Hilden, Germany) and reverse transcribed 
to obtain cDNA using the Ready-to-Go T-Primed 
First-Stand Kit (Amersham Biosciences, Little 
Chalfont, UK). The cDNA was used as a template in 
the StepOnePlus Real-Time PCR System (Applied 
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Biosystems, Foster City, CA, USA), with the BDNF 
(GenBank Accession Number NM_012513) FW-
primer 5′-GCG GCA GAT AAA AAG ACT GC-3′ 
and RV-primer 5′-GCA GCC TTC CTT CGT GTA 
AC-3′, which generated a product of 141 bp, and the 
ribosomal protein L27 RPL-27 (GenBank Accession 
Number NM_022514) FW-primer 5′-GAA TTG 
ACC GCT ATC CCA GA-3′ and RV-primer 5′-TCG 
CTC CTC AAA CTT GAC CT-3′, which generated 
a product of 230 bp as an internal control.
   Primers were designed to target EGFP and the 
S-Tag, which were the common parts of each vector, 
to detect the mRNA expression of the GFP-fusion 
gene in the tissues of the vector-administered rats; 
the primers were GFP FW-primer 5′-CGA CAA 
CCA CTA CCT GAG CA-3′ and RV-primer 5′-GAA 
TTT AGC AGC AGC GGT TT-3′, which generated 
a product of 178 bp. QRT-PCR was performed, 
and the expression levels of GFP and RPL-27 were 
compared between the vector administration groups 
and the vector non-administration group.
Immunohistochemistry
   To confirm that the gene in the administered 
vector was expressed in rats, TrkB-GFP protein 
expression was evaluated. Perfusion fixation of the 
TM (+) group rats on days 7 and 9 was performed 
using 4% paraformaldehyde. Subsequently, the 
spinal cord was resected in sections from T10 to 
L5. The expression of TrkB-GFP in each specimen 
was observed with anti-GFP antibody mouse 
monoclonal IgG2a (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) and FITC-labeled goat 
anti-mouse IgG2a (Santa Cruz Biotechnology) as 
a secondary antibody. Nuclei were stained with 
4′,6-diamidino-2-phenylindole (DAPI, DOJINDO 
LABORATORIES, Kumamoto, Japan) to examine 
the localization of the cells.
Statistical analysis
   Statistical analyses of the results were performed 
using GraphPad Prism6. The von Frey test results 
were analyzed by repeated measures two-way 
analysis of variance (ANOVA) and Sidak’s post-
hoc tests. Gene expression results were evaluated 
by Student’s t-tests. Experts reviewed the statistics, 
and the data were checked, confirming them for 
normality. A value of p < 0.05 was considered 
statistically significant.
RESULTS
Expression of the modified TrkB receptors in 
HEK293 cells
   We constructed two GFP-expression vectors 
expressing truncated TrkB lacking the intracellular 
tyrosine kinase domain (Fig. 1), and transfected 
them into HEK293 cells to confirm gene expression. 
In cells treated with the empty vector, fluorescent 
protein expression was observed in the whole cell 
(Fig. 2A). In cells treated with the TM (+) vector 
(with a transmembrane domain), the fluorescent 
protein was expressed in the vicinity of the cell 
membrane (Fig. 2B), indicating that the modified 
TrkB protein with its transmembrane domain 
localized on the cell membrane. However, in 
cells treated with the TM (-) vector (without a 
transmembrane domain), GFP expression was 
weakly observed in the cytoplasm (Fig. 2C), 
suggesting a possibility that the modified TrkB 
protein without a transmembrane domain is secreted 
into the culture medium.
   To verify the possibility, we performed a pull-
down assay with S-tag protein agarose beads and 
western blotting with anti-FLAG antibody using 
the culture medium. As the modified TrkB protein 
is a fused protein with S-tag and FLAG-tag, it was 
expected that we can detect the protein by pull-
down assay and western blotting, if the protein is 
secreted into the culture medium. Secreted TM (-) 
protein was confirmed in culture medium of cells 
transfected with the TM (-) vector by a pull-down 
assay with S-tag protein agarose beads and western 
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Figure 1   Construction of the truncated TrkB expression vectors.
Fig. 1. Construction of the truncated TrkB expression vectors.
Based on the rat TrkB gene (GenBank Accession No. M55291), two extracellular regions of the TrkB cDNA were amplified by 
PCR and fused with the GFP cDNA in-frame in the expression vectors. The truncated TrkB that lacked a transmembrane domain 
was referred to as TM (-), the truncated TrkB with a transmembrane domain was referred to as TM (+). EGFP, enhanced green 
fluorescence protein; TM, transmembrane.
Fig. 2. Confirmation of the expression of modified receptor proteins.
The empty vector, TM (+) vector, and TM (-) vector were transfected into the human kidney cell line HEK293. (A) Fluorescence 
protein expression was observed in the whole cell in cells treated with the empty vector. (B) Fluorescent protein expression 
was observed in the membranes of cells treated with the TM (+) vector. (C) Cells treated with the TM (-) vector showed weak 
fluorescent protein expression. Upper, photograph of cellular localization of EGFP-fused protein; lower, Intensity of EGFP-fused 
protein on cross section of a cell. (D) The presence of TM (-) protein secreted in culture medium of cells transfected with the TM (-) 
vector was confirmed by western blotting with anti-FLAG antibody after pull-down assay with S-tag protein agarose beads. Lane 1, 
empty vector; lane 2, TM (-) vector.
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blotting with an anti-FLAG antibody (Fig. 2D, lane 
2), but not in culture medium of the empty vector-
transfected cells (Fig. 2D, lane 1).
Confirmation of the BDNF-binding ability of the 
modified TrkB proteins
   After confirming that the modified TrkB proteins 
were expressed in HEK293 cells, we examined the 
BDNF-binding ability of the TrkB proteins, using 
the transfected HEK293 cells. For TM (+), the 
HEK293 cells transfected with the vectors were co-
cultured with BDNF, and BDNF interactions with 
the cell membrane were detected using an anti-
BDNF antibody. Cells treated with the empty vector 
did not show BDNF binding (Fig. 3, A1, A2, B1, 
and B2), while cells treated with the TM (+) vector 
showed localization of GFP (green) and BDNF (red) 
at the cell membrane surface (Fig. 3, C1, C2, D1, 
and D2), suggesting that the TM (+) protein is able 
to bind to BDNF at the cell membrane surface.
   For TM (-), the supernatant was collected from 
the culture medium of the vector-transfected 
cells, BDNF was added and mixed. After TM (-) 
protein was pulled down with S-tag protein agarose 
beads, BDNF was detected by western blotting 
using an anti-BDNF antibody. It was expected 
that we can detect BDNF by pull-down assay and 
western blotting, if TM (-) protein secreted from 
the transfected cells can bind with BDNF. BDNF 
was detected using the culture medium of the TM 
(-) transfected cells (Fig. 3E, lane 2), but was not 
detected using the culture medium of the empty 
vector-transfected cells (Fig. 3E, lane 1), suggesting 
that the TM (-) protein secreted from cells is able to 
bind with BDNF.
Development of a cancer pain rat model
   After confirming that the modified TrkB receptor 
proteins could bind to BDNF, we developed a cancer 
pain rat model to examine the analgesic effect of the 
Figure 3   Conﬁrmation of the BDNF binding capacity of the modiﬁed receptor proteins.
A1 A2
B1 B2
C1 C2
D1 D2
Empty vector
TrkB-GFP  anti-BDNF-AbGFP  anti-BDNF-Ab
anti-BDNF antibody
E.  BDNF-binding of TM (–) 
M   1    2
200
116
97
66.2
45
31
14.4
6.5
21.5
kD
Fig. 3. Confirmation of the BDNF binding capacity of the modified receptor proteins
For TM (+), HEK293 cells transfected with the vectors were co-cultured with BDNF, washed and reacted with anti-BDNF rabbit 
antibody/Cy3-labeled anti-rabbit antibody. A and B show the cells transfected with empty vector, and C to D show the cells 
transfected with the TM (+) vector. Number 1 indicates the localisation of GFP (green), and number 2 indicates the localisation 
of BDNF (red). Localization of BDNF was detected on the cells transfected with TM (+) (C2 and D2), but not on the cells 
transfected with the empty vector (A2 and B2).  For TM (-), after adding BDNF to the culture medium collected from cells 
transfected with the vectors, BDNF-binding of TM (-) protein was detected by pull-down assay with S-tag protein agarose beads 
and western blotting with anti-BDNF antibody. E lane 1, empty vector; lane 2, TM (-) vector; M, molecular weight marker.
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modified TrkB, TM (+), and TM (-), on cancer pain. 
A model rat was created by injecting MRMT-1 rat 
breast cancer cells into the intramedullary cavity of 
the tibia of the left leg of male Wistar rats. We then 
evaluated the presence of bone fusion using X-rays 
to confirm MRMT-1 cell colonization. We punctured 
the epiphyseal growth plate 5 mm at the tip side 
from the knee of the left leg with a 23-G needle to 
the marrow and injected the cancer cells (3.0 × 
103 cells/10 μL). Day 0 was normal, before cancer 
cell inoculation. Bone fusion gradually progressed 
from day 7 and laterality in the permeability of the 
bones was recognized clearly after day 14. We kept 
only one rat until day 21; however, bone fusion was 
remarkable, and the continuity of the bone tissue 
was lacking. Plain X-rays were obtained on days 0, 
7, and 14, and from one rat on day 21 (Fig. 4). We 
observed clear bone fusion on the ipsilateral side at 
day 14; by day 21, we detected a colony of cancer 
cells.
Analgesic effect of the modified TrkB vectors on 
cancer pain rats
   The growth of inoculated cancer cells was 
confirmed successfully on the ipsilateral side of 
the model rats. The rats were then administered a 
transfection reagent with/without vector DNAs into 
the spinal cord at day 7, and pain was examined 
by von Frey tests from day 0. The results of the 
von Frey tests for the vector non-administration 
group (by transfection reagent without vector DNA) 
are summarized in Fig. 5. There was a significant 
decrease (p < 0.05) in the 50% paw withdrawal 
threshold (PWT) on the ipsilateral side after 
day 7, which indicated a state of pain irritation. 
This decrease in the 50% PWT did not improve 
Day 0 
Day 7 
Day 14 
Day 21 
ipsilateral 
Radiographic analysis of rat tibia Figure 4 
Fig. 4. Radiographical analysis of the rat tibia.
We evaluated the presence of bone fusion using X-rays 
to confirm MRMT-1 cell colonization. We punctured the 
epiphyseal growth plate 5 mm at the tip side from the knee 
of the left leg with a 23-G needle to the marrow and injected 
the cancer cells (3.0 × 103 cells/10 μL). Day 0 was normal, 
before cancer cell inoculation. The bone fusion gradually 
progressed from day 7 and laterality in the permeability of 
bones was clearly recognized after day 14. We kept only one 
rat until day 21; however, bone fusion was remarkable, and 
the continuity of the bone tissue was lacking.
Fig. 5. Pain evaluation for the vector non-administration 
group.
Cancer cells were inoculated on day 0, and the vector non-
administration group rats were administrated by transfection 
reagent without vector DNAs at day 7. After each rat rested 
quietly in a cage in a dark room for at least 30 min, the 50% 
PWT was measured using von Frey tests with filaments of 
0.4, 0.6, 1.0, 1.4, 2.0, 4.0, 6.0, 8.0, and 15.0 g. The 50% 
PWT of the ipsilateral side gradually decreased and was 
significantly different from that of the contralateral side after 
day 7. The threshold for the ipsilateral side did not increase 
spontaneously, and there was no tendency for that of the 
contralateral side to decrease. Pain irritation only occurred on 
the ipsilateral side, which was injected with the cancer cells. 
A statistical analysis was performed using repeated measures 
two-way analysis of variance (ANOVA) and Sidak’s post-hoc 
tests implemented in GraphPad Prism6. Data are represented 
as the mean± standard deviation. 50% PWT, 50% paw 
withdrawal threshold. *, p < 0.05 between the ipsilateral and 
the contralateral sides.
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spontaneously by day 14. Additionally, a reduction 
in the 50% PWT on the contralateral side was not 
found.
   For the vector-administered groups, in the empty 
vector group, the 50% PWT of the ipsilateral 
side decreased significantly (p < 0.05), similar to 
the vector non-administration group (Fig. 6A). 
The TM (+) group showed pain irritation before 
vector administration; however, the threshold on 
the ipsilateral side increased to the same extent 
as that on the contralateral side by day 9 (Fig. 
6B), suggesting that TM (+) vector administration 
had an analgesic effect on cancer pain, to a level 
comparable to a painless state on day 2 after vector 
administration. The thresholds decreased and a 
significant difference was observed at day 14 (1 
week after vector administration). In the TM (-) 
group, the 50% PWT level was significantly lower 
than that of the contralateral side on day 5 and day 7 
(Fig. 6C). However, the 50% PWT increased to the 
approximate value of the contralateral side at day 9. 
The 50% PWT decreased at day 12 and day 14, but 
a higher 50% PWT than those of day 5 and day 7 
was maintained.
Confirmation of BDNF expression in the DRG of 
cancer pain rats
   To assess the increased expression of the BDNF 
gene induced by pain signaling in cancer pain rats, 
we evaluated BDNF mRNA expression in the L3 
DRG and spinal cord, normalized against RPL-27 
mRNA expression at the same sites. We calculated 
the ratio of ipsilateral BDNF mRNA to RPL-27 
mRNA when expression on the contralateral side 
in the DRG was set to 1. The expression of BDNF 
mRNA was significantly higher on the ipsilateral 
side than in the contralateral side in both the vector 
non-administration group (n = 8, p < 0.0001, one-
tailed Student’s t-test) and the vector administered 
groups (n = 34, p < 0.0001) (Fig. 7), suggesting 
that BDNF expression is induced in the DRG by 
pain signaling in our cancer pain model rats, which 
Fig. 6. Pain evaluation for the vector-administered group.
Von Frey tests were performed to evaluate pain in each vector-administered group. (A) In the empty vector group, the state of 
pain irritation was significant and was similar to the vector non-administration group; the threshold on the contralateral side did 
not decrease. (B) Plot of the von Frey test results for the TM (+) group. The 50% PWT of the ipsilateral side gradually decreased, 
similar to the vector non-administration group. After the vector administration (on day 7), the threshold of the ipsilateral side 
increased at day 9 to a level similar to that of the contralateral side. However, the threshold decreased, with a significant difference 
between sides at day 14, and a state of pain recurred. (C) Plot of von Frey test results for the TM (-) group. The 50% PWT of the 
ipsilateral side gradually decreased, similar to the vector non-administration group, and we observed a state of pain irritation from 
day 5 to day 7. By the vector administration (on day 7), the 50% PWT of the ipsilateral side increased and there was no significant 
difference between sides. The 50% PWT tended to decrease again gently at day 12 and day 14. A significant difference between 
sides was not observed on day 12 and day 14. Arrows on day 7 show vector administration. 50% PWT, paw withdrawal threshold; 
*, p < 0.05 between the ipsilateral and the contralateral sides.
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was consistent with previous results９）. The BDNF 
mRNA expression level in the spinal cord did not 
differ between the two sides (data not shown).
Confirmation of mRNA and protein expression of 
the modified TrkB in treated rats
   The mRNA expression levels of TrkB-GFP from 
the vectors administered to the L3 spinal cord of 
TM (+) rats were examined by qRT-PCR. Using 
PCR primers targeting GFP, we detected the 
expression of TrkB-GFP in the L3 spinal cord on the 
ipsilateral site of TM (+) rats on days 9, 12, and 14; 
data are shown as relative values to RPL-27 mRNA 
expression levels as an internal control (Fig. 8).
   Protein expression of TrkB-GFP after vector 
administration to the spinal cords of rats was 
examined by immunohistochemistry. We performed 
perfusion fixation of TM (+) group rats on day 9 
with 4% paraformaldehyde, and the spinal cord 
tissue specimens, which were resected in sections 
from T10 to L5, were reacted with a mouse anti-
Fig. 7. Expression of BDNF mRNA in the L3 DRG of cancer pain rats.
BDNF mRNA expression in the dorsal root ganglion (DRG) of L3 on the contralateral and ipsilateral sides at day 14 was analyzed 
by quantitative real-time reverse transcription PCR (qRT-PCR), normalizing against RPL-27 mRNA expression. The expression 
ratio on the contralateral side was set at 1. BDNF mRNA expression was significantly higher in the vector non-administration 
group (n = 8) (A), and in the vector administration group (n = 34) (B), on the ipsilateral side than in the contralateral side. BDNF 
mRNA expression at the ipsilateral side of the DRG in the vector non-administration group was similar to that of the vector 
administrated group. RPL-27, ribosomal protein L27: *, p < 0.05 between the ipsilateral and the contralateral sides.
Fig. 8. Detection of TrkB-GFP mRNA in the L3 spinal cord 
of TM (+) rats
Relative expression of the TrkB-GFP mRNA in TM (+) rats 
after TM (+) administration on day 7. The exogenous TrkB-
GFP mRNA expression in the L3 spinal cord of TM (+) group 
on days 9, 12, and 14 was examined by quantitative real-time 
reverse transcription PCR (qRT-PCR) with GFP primers, to 
eliminate the endogenous TrkB mRNA, and normalized by 
RPL-27 mRNA as an internal control. RPL-27; ribosomal 
protein L27.
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GFP antibody and FITC-labeled anti-mouse 
antibodies (Fig. 9). We detected the GFP-fusion 
protein along the surface cells of the L3 spinal 
cord at the ipsilateral side (Fig. 9A) of TM (+) 
rats (Fig. 9B-D), but not in rats of the vector non-
administration group (Fig. 9E-F).
DISCUSSION
   Based on the BDNF expression in the DRG and 
the von Frey test results using the vector non-
administration group, our cancer pain model rats 
were in a state of pain irritation after the injection 
of MRMT-1 cells. The TM (-) and TM (+) groups 
escaped the state of pain irritation, while the empty 
vector group showed similar von Frey test results 
to those of the vector non-administration group. 
Figure 9   Detection of TrkB-GFP protein in the L3 spinal cord of TM (+) rats
vector non-administration rat
E.  DAPI F.  GFP
TM (＋) rat
B. DAPI C.  GFP D.  Merge
ipsicontra
A. HE staining of the spinal cord for L3
Ventral 
Fig. 9. Detection of TrkB-GFP protein in the L3 spinal cord of TM (+) rats.
(A) HE staining of the spinal cord for L3. Other panels show an extended image of the dorsal spinal cord surface at ipsilateral 
side. (B, C) In the L3 spinal cord two days (on day 9) after TM (+) administration, the expression of GFP proteins was detected, 
similar to the site marked by DAPI staining. (D) Merged image of GFP and DAPI staining two days after TM (+) administration. (E, 
F) DAPI and GFP imaging in rats of the vector non-administration group on day 9. We observed scattered DAPI staining, but did 
not detect GFP proteins around the cells, even when we increased the brightness. HE, Hematoxylin-Eosin; contra, contralateral; 
ipsi, ipsilateral; DAPI, 4′,6-diamidino-2-phenylindole. Scale bar, 50 μm.
These results indicated that an analgesic effect was 
obtained by the administration of the modified 
TrkB vectors. Complications, such as paralysis, 
mechanical complications by catheterization, 
or chemical complications related to vector 
administration, did not appear to influence the von 
Frey test results or the analgesic effects. On the 
basis of a radiological analysis and von Frey tests, 
14 days was sufficient to confirm the outcomes of 
the pain irritation model and vector administration. 
Accordingly, extending the cancer pain model to 
beyond 14 days was deemed unethical.
   In a transfection assay with HEK293 cells, the 
secreted TM (-) protein was detected in the culture 
medium, while some was detected in cells. On 
the basis of a luciferase assay using a fusion gene 
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of luciferase with the N-terminal signal peptide 
sequences of TrkB, we confirmed that the fusion 
protein was secreted outside of the cells (data not 
shown). We speculated that TM (-) proteins were 
secreted from cells under the arachnoid cells of the 
spinal cord, and bound to BDNF in the subarachnoid 
space of the model rats. TM (+) protein with its 
transmembrane domain was detected in the vicinity 
of the cell membrane. The TM (+) protein might 
localize to the cell membrane via its transmembrane 
domain. TM (+) protein may function as a local 
analgesic agent and TM (-) protein may function 
as a humoral analgesic agent. Further large-scale 
studies are required to clarify the duration of the 
analgesic effect, the stability of the proteins, and 
the location and frequency of BDNF binding in the 
presence or absence of the transmembrane domain.
   Full-length TrkB has an intracellular tyrosine 
kinase domain, while one isoform, a truncated TrkB 
lacking the intracellular tyrosine kinase domain, has 
also been reported18）. There are various opinions 
regarding the roles of truncated TrkB. Eide et 
al.19） reported that truncated TrkB functions as a 
dominant negative receptor for BDNF and that full-
length TrkB is involved in PLC-γ-dependent nerve 
communication. Truncated TrkB might conflict with 
pain communication mediated by BDNF and full-
length TrkB, which would be consistent with the 
results of the present study. Associations of BDNF 
with neuropathic pain, inflammatory pain, and 
various other pain models have been reported７）. 
Obata et al.20） reported that neuropathic pain could 
be inhibited by downregulating the expression of 
BDNF. Thus, similar analgesic effects might be 
obtained in other pain models by the administration 
of our truncated TrkB vectors.
   BDNF is essential for the maintenance of 
neurological function, including nervous system 
maturation and cell survival21，22）. Additionally, 
BDNF is associated with various diseases and 
organs, e.g., neurodegenerative diseases, such as 
Alzheimer disease23） or Parkinson’s disease24）. 
Associations with myocardial contractility25） or 
cardiac microvessel stabilization26） have also 
been reported. Recently, an association between 
BDNF and depression was reported. Levels of the 
neurotrophic factor decrease mainly in response to 
long-term exposure to stress, and neuropoiesis in the 
hippocampus is inhibited by a decrease in BDNF. 
The hippocampus plays an important role in the 
control of emotions, and depressive symptoms are 
thought to result from its functional inhibition27）. 
BDNF exhibits clear associations with systemic 
organs. Thus, it may not be suitable to treat the 
whole body by the transvenous administration of 
truncated TrkB vectors because of potential side 
effects. Furthermore, long-term administration may 
cause neurological complications; therefore, limited, 
short-term use, such as for the advanced stages of 
cancer pain, or local application may be preferred.
   We assessed the analgesic effects based on 
rat behavior and confirmed the presence of the 
exogenous modified TrkB mRNA in the treated 
rats. Furthermore, we confirmed the presence of the 
modified TrkB protein immunohistologically in the 
L3 spinal cord of treated rats. The modified TrkB 
protein was detected mostly in the spinal dorsum, 
which might receive the vectors, and was minimal 
around the intraspinal cells. The present study had 
a few limitations. We did not confirm whether 
the exogenous modified TrkB receptors inhibited 
endogenous TrkB-BDNF binding competitively, 
and we did not evaluate histological markers and 
physiological analgesic effects. Further studies are 
necessary to examine the analgesic effects and their 
underlying mechanisms comprehensively.
   In summary, we administered two truncated TrkB 
vectors lacking intracellular tyrosine kinase domain. 
We observed an analgesic effect in a bone cancer 
pain rat model. This is the first report of an analgesic 
effect on cancerous bone pain using this method, 
and a similar strategy might induce analgesic effects 
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in other pain models. Additional studies are needed 
to assess the clinical applications of this method.
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